Hipril A Tablet contains a combination of Amlodipine 5 mg and Lisinopril 5 mg, utilized primarily for the management of hypertension and related cardiovascular conditions. Amlodipine, a calcium channel blocker, acts by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure. Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, which leads to vasodilation, decreased aldosterone secretion, and reduced blood volume. The combined effect of these agents provides enhanced antihypertensive efficacy through complementary mechanisms, improving blood pressure control and reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Hipril A is indicated for patients who require dual therapy due to inadequate response to monotherapy. It is essential to monitor renal function and serum electrolytes periodically during treatment, as Lisinopril may cause hyperkalemia and renal impairment. Common adverse effects include dizziness, headache, cough, and peripheral edema. This medication should be used under medical supervision, with caution in patients with a history of angioedema, renal artery stenosis, or pregnancy.